Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients

Blood

Volumn 105, Issue 9, 2005, Pages 3472-3479

  Houwerzijl, Ewout J ^b   Blom, Nel R ^b   Van Der Want, Johannes J L ^b   Louwes, Henk ^b   Esselink, Mariet T ^b   Smit, Jan W ^b   Vellenga, Edo ^b   De Wolf, Joost Th M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CATHEPSIN D; GLYCOCALICIN; THROMBOPOIETIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CELL DEATH; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LIFESPAN; MALE; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 18244369756     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-06-2108     Document Type: Article

References (62)

1. Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
2. Heaney ML, Golde DW. Myelodysplasia. New Engl J Med. 1999;340:1649-1660.
3. Brada S, de Wolf J, Hendriks D, Esselink M, Ruiters M, Vellenga E. The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36- sorted bone marrow cells of myelodysplasia patients. Blood. 1996;88:505-510.
4. Brada SJ, de Wolf JT, Hendriks DW, Smit JW, Vellenga E. CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation. Leukemia. 1998;12:882-886.
5. Hofmann WK, Kalina U, Koschmieder S, Seipelt G, Hoelzer D, Ottmann OG. Defective megakaryocytic development in myelodysplastic syndromes. Leuk Lymph. 2000;38:13-19.
6. Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol. 1998;101:220-230.
7. van de Loosdrecht AA, Vellenga E. Myelodysplasia and apoptosis: new insights into ineffective erythopoiesis. Med Oncol. 2000;17:16-21.
8. Lambertenghi Delillers G, Annaloro C, Oriani A, Soligo D. Myelodysplastic syndrome associated with bone marrow fibrosis. Leuk Lymphoma. 1992;8:51-55.
9. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalties in myelodysplastic syndromes: I, serum immunoglobulins and autoantibodies. Br J Haematol. 1986;63:143-147.
10. Hall AG, Proctor SJ, Saunders PW. Increased platelet associated immunoglobulin in myelodysplastic syndromes. Br J Haematol. 1987;65:245-246.
11. Billström R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes: clinical and cytogenetic features. Eur J Haematol. 1995;55:42-48.
12. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79:1548-1551.
13. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699-705.
14. Stadtmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndromes. Br J Haematol. 1991;77:502-508.
15. Wattel E, Cambier N, Caulier M-T, Sautière D, Bauters F, Fenaux P. Androgen therapy in myelodyplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol. 1994;87:205-208.
16. Bourgeois E, Caulier MT, Rose C, Dupriez B, Bauters F, Fenaux P. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report of six cases. Leukemia. 2001;15:950-953.
17. Steinberg MH, Kelton JG, Coller BS. Plasma glycocalicin: an aid in the classification of thrombocytopenic disorders. New Engl J Med. 1987;317:1037-1042.
18. Houwerzijl EJ, Louwes H, Smit JW, Esselink MT, Vellenga E, de Wolf JTh. Glycocalicin index is increased in ITP patients with a decreased platelet production rate in the platelet kinetic studies [abstract]. Blood. 2001;98:525a.
19. Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500-506.
20. Jäättelä M, Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol. 2003;4:416-423.
21. Lockshin RA, Zakeri Z. Caspase-independent cell deaths. Curr Opin Cell Biol. 2002;14:727-733.
22. Leist M, Jäättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001;2:589-598.
23. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
24. Louwes H, Zeinali Lathori OA, Vellenga E, de Wolf JT. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med. 1999;106:430-434.
25. International Committee on Standardization in Hematology panel on diagnostic application of radioisotypes in haematology: recommended method for Indium-111 platelet survival studies. J Nucl Med. 1988;29:564-566.
26. Louwes H, Schuurman JJ. Platelet labelling with 111In-tropolonate. In: Kessler CH, Hardeman MR, Henningsen H, Petrovici JN, eds. Clinical Application of Radiolabelled Platelets. Dordrecht, the Netherlands: Kluwer Academic; 1990:45-60.
27. Bentfeld-Barker ME, Bainton DF. Ultrastructure of rat megakaryocytes after prolonged thrombocytopenia. J Ultrastruct Res. 1977;61:201-214.
28. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026.
29. Öllinger K. Inhibition of cathepsin D prevents free-radical-induced apoptosis in rat cardiomyocytes. Arch Biochem Biophys. 2000;373:346-351.
30. Kågedal K, Johansson U, Öllinger K. The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress. FASEB J. 2001;15:1592-1594.
31. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;66:1105-1109.
32. Tomer A, Hanson SR, Harker LA. Autologous platelet kinetics in patients with severe thrombocytopenia: discrimination between disorders of production and destruction. J Lab Clin Med. 1991;118:546-554.
33. Hebbar M, Kaplan C, Caulier MT, et al. Low incidence of specific anti-platelet antibodies detected by MAIPA assay in the serum of thrombocytopenic MDS patients and the lack of correlation between platelet autoantibodies and the response to danazol therapy. Br J Haematol. 1996;94:112-115.
34. Najean Y, Lecompte T. Chronic pure thrombocytopenia in the elderly patients: an aspect of the myelodysplastic syndrome. Cancer. 1989;64:2506-2510.
35. Stratton JR, Ballem PJ, Gernsheimer T, Cerqueira M, Slichter SJ. Platelet destruction in autoimmune thrombocytopenic purpura: kinetics and clearance of indium-111-labeled autologous platelets. J Nucl Med. 1989;30:629-637.
36. Efira A, Cauchie P, Rauis M, de Maertelaere E. Platelet survival in myelodysplastic syndromes. Acta Haemat. 1986;76:124-126.
37. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodyplastic syndrome: morphological and ultrastructural assessment. Leukemia. 1997;11:656-659.
38. Sakura T, Murakami H, Saitoh T, Naruse T, Tsuchiya J. Ultrastructural abnormalities of bone marrow erythroblasts in refractory anemia. Ultrastruct Pathol. 1998;22:173-180.
39. Shetty V, Hussaini S, Alvi S, et al. Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients. Br J Haematol. 2002;116:817-825.
40. van de Loosdrecht AA, Brada SJ, Blom NR, et al. Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia: an ultrastructural analysis. Leuk Res. 2001;25:385-393.
41. Cohen AM, Alexandrova S, Bessler H, Mittelman M, Cycowitz Z, Djaldetti M. Ultrastructural observations on bone marrow cells of 26 patients with myelodysplastic syndromes. Leuk Lymph. 1997;27:165-172.
42. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. "Low-risk" myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus antiapoptotic bcl-2-related proteins. Br J Haematol. 1998;103:1075-1082.
43. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268-276.
44. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995;89:67-71.
45. Mundle S, Iftikhar A, Shetty V, et al. Novel in situ double labeling for simultaneous detection of proliferation and apoptosis. J Histochem Cytochem. 1994;42:1533-1537.
46. Brada SJ, van de Loosdrecht AA, Koudstaal J, de Wolf JTh, Vellenga E. Limited numbers of apoptotic cells in paraffin embedded bone marrow samples of patients with myetodysplastic syndrome. Leuk Res. 2004;28:921-925.
47. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol. 1996;95:368-371.
48. Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood. 2002;100:4427-4432.
49. Hellström-Lindberg E, Kanter-Lewensohn L, Öst A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-csf and erythropoietin. Leuk Res. 1997;21:415-425.
50. Delforge M, Raets V, Van Duppen V, Boogaerts M. Amifostine does not preferentially stimulate the growth of residual polyclonal progenitor cells in myelodysplastic syndromes. Leuk Res. 2003;27:593-598.
51. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176-188.
52. Vercammen D, Vandenabeele P, Beyaert R, Declercq W, Fiers W. Tumour necrosis factor-induced necrosis versus anti-Fas-induced apoptosis in L929 cells. Cytokine. 1997;9:801-808.
53. Vercammen D, Brouckaert G, Denecker G, et al. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med. 1998;188:919-930.
54. Luschen S, Ussat S, Scherer G, Kabelitz D, Adam-Klages S. Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling: requirement of cell cycle progression. J Biol Chem. 2000;275:24670-24678.
55. Vanden Berghe T, van Loo G, Saelens X, et al. Differential signaling to apoptotic and necrotic cell death by Fas-associated death domain protein FADD. J Biol Chem. 2004;279:7925-7933.
56. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1:489-495.
57. Hetz CA, Hunn M, Rojas P, Torres V, Leyton L, Quest AF. Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: onset of necrosis is associated with delayed ceramide increase. J Cell Sci. 2002;115:4671-4683.
58. Zhao S, Yang YN, Song JG. Ceramide induces caspase-dependent and -independent apoptosis in A-431 cells. J Cell Physiol. 2004;199:47-56.
59. Garcia-Ruiz C, Colell A, Mari M, Morales A, Fernandez-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species: role of mitochondrial glutathione. J Biol Chem. 1997;272:11369-11377.
60. Heinrich M, Wickel M, Schneider-Brachert W, et al. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 1999;18:5252-5263.
61. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10:299-304.
62. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysptasia. Blood. 2004;103:2316-2324.